LifeArc
7
2
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Multi-Omic SignAtures of Inflammatory Cutaneous Diseases
Role: collaborator
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II
Role: collaborator
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
Role: collaborator
Telehealth in MND-Research (TIM-R): A Research Database for MND
Role: collaborator
ANNE Sensor Monitoring in Cystic Fibrosis
Role: collaborator
Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
Role: collaborator
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
Role: collaborator
All 7 trials loaded